Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.
- Conditions
- Chronic Graft Versus Host Disease
- Interventions
- First Posted Date
- 2023-11-22
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 260
- Registration Number
- NCT06143891
- Locations
- 🇮🇹
Investigational Site Number : 3800011, Pavia, Italy
🇮🇹Investigational Site Number : 3800010, Perugia, Italy
🇮🇹Investigational Site Number : 3800006, Reggio Calabria, Italy
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
- Conditions
- Multiple Sclerosis
- Interventions
- Drug: Placebo infusionDrug: Placebo tabletDrug: MRI contrast-enhancing agents
- First Posted Date
- 2023-11-21
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1400
- Registration Number
- NCT06141473
- Locations
- 🇮🇹
Investigational Site Number : 3800014, Chieti, Italy
🇮🇹Investigational Site Number : 3801027, Cuneo, Italy
🇮🇹Investigational Site Number : 3800020, Verona, Italy
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
- Conditions
- Multiple Sclerosis
- Interventions
- First Posted Date
- 2023-11-21
- Last Posted Date
- 2025-03-11
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 900
- Registration Number
- NCT06141486
- Locations
- 🇨🇳
Investigational Site Number : 1560008, Beijing, China
🇨🇳Investigational Site Number : 1560003, Changchun, China
🇨🇳Investigational Site Number : 1560011, Changsha, China
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
- First Posted Date
- 2023-11-14
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 601
- Registration Number
- NCT06130566
- Locations
- 🇬🇷
Investigational Site Number : 3000002, Thessaloniki, Greece
🇬🇷Investigational Site Number : 3000003, Thessaloniki, Greece
🇮🇳Investigational Site Number : 3560001, Ahmedabad, India
Proof-of-concept Study Evaluating Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
- First Posted Date
- 2023-11-07
- Last Posted Date
- 2025-02-26
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 90
- Registration Number
- NCT06118099
- Locations
- 🇺🇸
Medical Dermatology Specialists Site Number : 8400002, Phoenix, Arizona, United States
🇺🇸Center for Dermatology Clinical Research Site Number : 8400010, Fremont, California, United States
🇺🇸Corazon USA, LLC (DBA Life Clinical Trials) Site Number : 8400011, Margate, Florida, United States
Pharmacokinetic Study to Compare Itepekimab Exposure When Administered With an Autoinjector Versus Prefilled Syringe
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- First Posted Date
- 2023-11-02
- Last Posted Date
- 2023-11-02
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 90
- Registration Number
- NCT06114238
- Locations
- 🇺🇸
Clinical Pharmacology of Miami Site Number : 8400001, Miami, Florida, United States
FrexalimAB in Preservation of Endogenous insULIN Secretion Compared to Placebo in adUlts and Adolescents on Top of inSulin Therapy (FABULINUS)
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- First Posted Date
- 2023-11-01
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 192
- Registration Number
- NCT06111586
- Locations
- 🇺🇸
University of Florida College of Medicine- Site Number : 8400010, Gainesville, Florida, United States
🇺🇸AdventHealth Orlando- Site Number : 8400002, Orlando, Florida, United States
🇺🇸Joslin Diabetes Center - Boston- Site Number : 8400015, Boston, Massachusetts, United States
Study of the Tolerability and Pharmacokinetics of Oral Doses of SAR442168 With a Food Effect Investigation in Healthy Adult Participants
- First Posted Date
- 2023-10-30
- Last Posted Date
- 2023-10-30
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 71
- Registration Number
- NCT06106074
- Locations
- 🇺🇸
New Orleans Clinical Research Site Number : 8400001, Knoxville, Tennessee, United States
Dose Ranging Study of Lunsekimig Compared With Placebo-control in Adult Participants With Moderate-to-severe Asthma
- First Posted Date
- 2023-10-26
- Last Posted Date
- 2025-05-28
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 685
- Registration Number
- NCT06102005
- Locations
- 🇨🇳
Investigational Site Number : 1560013, Shanghai, China
🇨🇳Investigational Site Number : 1560015, Shenyang, China
🇨🇳Investigational Site Number : 1560005, Wenzhou, China
A Study Assessing Esophageal Function and Remodeling With Dupilumab Compared With Placebo for 24 Weeks Followed by 104 Weeks Open Label in Adult Participants With EoE (REMOdeling With Dupilumab in Eosinophilic Esophagitis Long-term Trial)
- First Posted Date
- 2023-10-25
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 64
- Registration Number
- NCT06101095
- Locations
- 🇮🇱
Investigational Site Number : 3760004, Jerusalem, Israel
🇮🇱Investigational Site Number : 3760003, Tel Aviv, Israel
🇨🇭Investigational Site Number : 7560002, Zürich, Switzerland